Background The aim of this study was to analyze the level of CD33 expression in patients
with newly diagnosed AML and determine its correlation with clinical characteristics …

CD33 is a myeloid differentiation antigen that is displayed on acute myeloid leukemia (AML)
blasts in most patients and, possibly, leukemic stem cells in some, and has thus served as …

CD33 is a myeloid cell surface antigen that is expressed on blast cells in acute myeloid
leukemia (AML) in a majority of all patients regardless of age or subtype of disease. The …

Expression patterns of CD33 and CD15 in normal/reactive bone marrow (n= 13) and in
leukemic blasts from patients with acute myeloid leukemia (n= 129) were determined using …

Highlights•This review provides a summary of the genetic, biological, and cellular
differences between adult and childhood acute myeloid leukemia (AML).•The role of …

Owing to the more recent positive results with the anti-CD33 immunotoxin gemtuzumab
ozogamicin, therapy against acute myeloid leukemias (AMLs) targeting CD33 holds many …

CD33 is a myeloid differentiation antigen with endocytic properties. It is broadly expressed
on acute myeloid leukemia (AML) blasts and, possibly, some leukemic stem cells and has …

Background We assessed for CD30 expression in patients with acute myeloid leukemia
(AML) or high-grade myelodysplastic syndrome (MDS) to examine the possibility that anti …

Background Study results on the prognostic value of CD11b for acute myeloid leukemia
(AML) patients are inconsistent. An up-to-date meta-analysis was conducted to assess the …

There is long-standing interest in therapies targeting fulllength CD33 (CD33FL) for acute
myeloid leukemia (AML)[1–3]. Longer survival with gemtuzumab ozogamicin (GO) in some …